Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of Statins
Figure 7
NAPLES II Study. This modified graphic of the NAPLES II study, confirmed with a randomized study, as compared to a control group, the favorable effect of statins before PCI. In individuals with stable coronary syndromes, statin-naive undergoing elective PCI, the administration of atorvastatin 80 mg/24 hours before PCI significantly reduces the incidence of MI-PCI associated (CPK-MB > 3x ULN, 2007 criteria). As can be seen, the benefit was especially significant in the subgroup of individuals with mg/L before PCI, in this subgroup the incidence of MI-PCI associated was 16.5% in the control group versus 4.6% in the atorvastatin group with .
